Charles Rudin

Charles Rudin has led the clinical development of DLL3-targeting therapies for small cell lung cancer, demonstrating that DLL3 (Delta-like ligand 3) is a highly selective surface marker on neuroendocrine tumors where Notch signaling is suppressed. His research established that DLL3 expression marks ASCL1-driven neuroendocrine SCLC cells and is absent from normal tissues, making it an ideal therapeutic target. He contributed to clinical trials of tarlatamab, a DLL3-targeting bispecific T-cell engager that achieved breakthrough therapy designation for SCLC. His work connecting Notch pathway biology to SCLC subtype classification has advanced precision medicine in this aggressive cancer.